Drug Profile
Research programme: osteoporosis therapeutics - Metabolic Pharmaceuticals/University of Auckland
Alternative Names: Adn 27-52; Am 1-8; MBP 0250; MBP 0260Latest Information Update: 11 May 2007
Price :
$50
*
At a glance
- Originator University of Auckland
- Developer Metabolic Pharmaceuticals; University of Auckland
- Class
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 31 Aug 2002 Preclinical trials in Osteoporosis in Australia (SC)
- 31 Aug 2002 Preclinical trials in Osteoporosis in New Zealand (SC)